Other diseases
IgA nephropathy
IgA 肾病
A kidney disease marked by immunoglobulin A deposits in the glomeruli.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 346
- cities
- 85
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 44% of the world's English-language research papers on IgA nephropathy, 2021–2025 (33% in 2016–2020), and 49% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
346 hospitals in 85 cities
Order: papers led on IgA nephropathy, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 1 papers or 1 trial on IgA nephropathy, or was a site in 1 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens IgA nephropathy in that city. 75 more cities are in the menu below.
- 65 papers led
- 35 papers ledNo open trial led
- 34 papers ledNo open trial led
- 22 papers led
- 21 papers ledNo open trial led
- 17 papers led
- 14 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers led
- 7 papers ledNo open trial led
- 7 papers led
- 7 papers led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 51
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 69 papers led4 hospitals
- 38 papers led4 hospitals
- 36 papers led5 hospitals
- 36 papers led2 hospitals
- 23 papers led6 hospitals
- 23 papers led4 hospitals
- 23 papers led2 hospitals
- 17 papers led1 hospital
- 16 papers led6 hospitals
- 15 papers led4 hospitals
- 14 papers led2 hospitals
- 14 papers led5 hospitals
- 14 papers led2 hospitals
- 13 papers led2 hospitals
- 13 papers led2 hospitals
- 11 papers led2 hospitals
- 10 papers led1 hospital
- 10 papers led1 hospital
- 9 papers led3 hospitals
- 9 papers led3 hospitals
- 8 papers led2 hospitals
- 8 papers led5 hospitals
- 8 papers led2 hospitals
- 7 papers led3 hospitals
- 7 papers led5 hospitals
- 7 papers led3 hospitals
- 7 papers led1 hospital
- 7 papers led5 hospitals
- 7 papers led2 hospitals
- 6 papers led2 hospitals
- 6 papers led2 hospitals
- 6 papers led3 hospitals
- 5 papers led1 hospital
- 4 papers led3 hospitals
- 4 papers led4 hospitals
- 4 papers led3 hospitals
- 3 papers led2 hospitals
- 3 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 1 paper led1 hospital
- 1 paper led0 hospitals
- 1 paper led1 hospital
- 1 paper led1 hospital
- 0 papers led0 hospitals
- 0 papers led0 hospitals
open trials on IgA nephropathy in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 13 Nov 2026, with at least one listed hospital as lead sponsor or site, and at least one listed hospital's site marked open. 15 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingA Study of SHR-2173 in Participants With Primary IgA Nephropathy
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07354932
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingA Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Registry
- NCT07375758
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPhase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07390123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang
- RecruitingA Study of YKST02 in Participants With Primary IgA Nephropathy
- Phase
- Early phase 1
- Started
- 2026-05
- Registry
- NCT07498673
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingAllogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07507201
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingA Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07582133
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2026-05
- Registry
- NCT07586267
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingEfficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
- Phase
- Phase 4
- Started
- 2026-06
- Registry
- NCT07604311
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingEvaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07614477
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingTo Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07822100
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingAnti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06792799
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingA Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06819826
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
- RecruitingA Trial of HRS-5965 Capsule in Primary IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-06
- Registry
- NCT07014826
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingNefecon and Ambrisentan in IgA Nephropathy
- Phase
- Phase 4
- Started
- 2025-09
- Registry
- NCT07030894
Age 18 years to 70 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingA Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07203404
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07305116
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingEarly Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07585981
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07616700
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEfficacy and Safety of Telitacicept in IgAN
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06654596
Age 18 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT06676007
Age 18 years to 75 years (registered criteria)
Led by Sichuan Provincial People's HospitalChengdu
- RecruitingClinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
- Phase
- Phase 2
- Started
- 2023-05
- Registry
- NCT05775042
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingThe Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04858724
Age not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCorrelation of Microbiome and Metabonomics With IgA Nephropathy
- Phase
- Not given
- Started
- 2020-05
- Registry
- NCT05190848
Age 16 years to 65 years (registered criteria)
Led by Guangdong Provincial People's Hospital; 4 listed hospitals as study sitesGuangzhou
- RecruitingIgA Nephropathy Biomarkers Evaluation Study (INTEREST)
- Phase
- Not given
- Started
- 2016-11
- Registry
- NCT02954419
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingIgA Nephropathy Registration Initiative of High Quality (INSIGHT)
- Phase
- Not given
- Started
- 2012-11
- Registry
- NCT03001947
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 13 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.